Show simple item record

dc.contributor.authorProdromou, C
dc.date.accessioned2018-08-29T08:36:07Z
dc.date.issued2009-11
dc.identifier15
dc.identifier.citationCURRENT TOPICS IN MEDICINAL CHEMISTRY, 2009, 9 pp. 1352 - 1368
dc.identifier.issn1568-0266
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2388
dc.identifier.doi10.2174/156802609789895656
dc.description.abstractHsp90 is involved in the maturation and activation of client proteins. Often these are key proteins involved in signal transduction and regulatory pathways that in a mutated and/or deregulated form sustain an oncogenic cellular state. Consequently, the malignancy is maintained with the aid of Hsp90 upon which the mutated proteins have become particularly dependent for their activity. The requirement for the Hsp90 chaperone machine to drive the malignancy makes Hsp90 a prime anticancer target, an ‘axle in a wheel’ that when disrupted has been shown to be effective in killing cancerous cells. This review aims to identify potential drug targets, based on the current structural knowledge of the Hsp90-chaperone machine, that could be targeted with the aim of disrupting its functioning and promoting an anti-cancer activity.
dc.format.extent1352 - 1368
dc.languageeng
dc.language.isoeng
dc.publisherBENTHAM SCIENCE PUBL LTD
dc.titleStrategies for Stalling Malignancy: Targeting Cancer’s Addiction to Hsp90
dc.typeJournal Article
rioxxterms.versionofrecord10.2174/156802609789895656
rioxxterms.licenseref.startdate2009-11
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfCURRENT TOPICS IN MEDICINAL CHEMISTRY
pubs.notesaffiliation: Prodromou, C (Reprint Author), Inst Canc Res, Chester Beatty Labs, Sect Struct Biol, 237 Fulham Rd, London SW3 6JB, England. Inst Canc Res, Chester Beatty Labs, Sect Struct Biol, London SW3 6JB, England. keywords: Heat shock protein; Hsp90; co-chaperones; cancer; drug design keywords-plus: HEAT-SHOCK-PROTEIN; ESCHERICHIA-COLI HSP90; N-TERMINAL DOMAIN; PHASE-II TRIAL; MOLECULAR CHAPERONE; CRYSTAL-STRUCTURE; ATPASE CYCLE; STEROID-RECEPTOR; ANTICANCER AGENT; STRUCTURAL BASIS research-areas: Pharmacology & Pharmacy web-of-science-categories: Chemistry, Medicinal author-email: [email protected] orcid-numbers: Prodromou, Chrisostomos/0000-0003-4320-1147 number-of-cited-references: 138 times-cited: 19 usage-count-last-180-days: 1 usage-count-since-2013: 3 journal-iso: Curr. Top. Med. Chem. doc-delivery-number: 532WZ unique-id: ISI:000272782400003 da: 2018-08-24
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR
pubs.volume9
pubs.embargo.termsNot known
dc.contributor.icrauthorProdromou, Chrisostomosen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following collection(s)

Show simple item record